Physician profile
Sara White
NPI 1336801406
$11,223.44
in general payments reported to CMS, 2019-2025
65 companies · $3,494 in 2025
The $3,494 reported for 2025 was more than what 98% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $328 · 2022: $1,187 · 2023: $2,936 · 2024: $3,279 · 2025: $3,494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,362 · Long Term Medical Supply Or Device Loan: $798 · Education: $549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,362.45 |
| Long Term Medical Supply Or Device Loan | $797.60 |
| Education | $548.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,925.09 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $846.66 | 2021-2025 | Enhertu, Imfinzi, Tagrisso |
| Janssen Biotech, INC. | $758.60 | 2022-2025 | Darzalex, Erleada, Rybrevant |
| Incyte Corporation | $591.23 | 2022-2025 | Jakafi, Monjuvi, Pemazyre |
| Celgene Corporation | $553.81 | 2022-2025 | Reblozyl, Breyanzi, Opdualag |
| Exelixis INC. | $429.50 | 2023-2025 | Cabometyx |
| Takeda Pharmaceuticals U.S.A., INC. | $386.40 | 2022-2025 | Fruzaqla, Alunbrig |
| Merck Sharp & Dohme LLC | $350.97 | 2023-2025 | Keytruda, Welireg |
| Genzyme Corporation | $343.48 | 2022-2025 | |
| Seagen INC. | $266.34 | 2021-2023 | Tukysa |
| Sobi, INC | $265.24 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $261.23 | 2023-2025 | Opdualag, Opdivo, Krazati |
| Genentech USA, INC. | $257.11 | 2022-2024 | Alecensa, Venclexta, Gavreto |
| Abbvie INC. | $231.97 | 2023-2025 | |
| Eisai INC. | $217.95 | 2022-2024 |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $184.07 | 2022-2023 | Jaypirca, Retevmo, Verzenio |
| Karyopharm Therapeutics INC. | $175.49 | 2022-2025 | Xpovio |
| Jazz Pharmaceuticals INC. | $172.27 | 2022-2025 | |
| Amgen INC. | $170.29 | 2021-2023 | Nplate, Vectibix, Xgeva |
| Bayer Healthcare Pharmaceuticals INC. | $169.84 | 2021-2025 | |
| Tersera Therapeutics LLC | $147.66 | 2023-2025 | Zoladex |
| Aveo Pharmaceuticals, INC. | $144.99 | 2023-2024 | Fotivda |
| Astellas Pharma US INC | $142.93 | 2023-2025 | Xtandi |
| Array Biopharma INC | $134.69 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Mirati Therapeutics, INC. | $118.16 | 2023-2024 | Krazati |
| Daiichi Sankyo INC. | $117.74 | 2022-2025 | Injectafer, Datroway, Enhertu |
| Genmab U.S., INC. | $114.82 | 2023-2025 | Epkinly |
| Puma Biotechnology, INC. | $106.14 | 2022-2023 | Nerlynx |
| Stemline Therapeutics INC. | $106.14 | 2024-2025 | Orserdu |
| Alexion Pharmaceuticals, INC. | $103.04 | 2022-2024 | Ultomiris |
| Emd Serono, INC. | $100.91 | 2023 | Bavencio, Tepmetko |
| Beigene USA, INC. | $99.95 | 2023-2024 | Brukinsa |
| Regeneron Healthcare Solutions, INC. | $89.56 | 2024 | Libtayo |
| Servier Pharmaceuticals LLC | $87.30 | 2022-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $78.36 | 2022-2023 | Imbruvica |
| Pharmaessentia USA Corporation | $74.69 | 2024-2025 | Besremi |
| Blueprint Medicines Corporation | $74.56 | 2024-2025 | Ayvakit |
| Kyowa Kirin, INC. | $64.96 | 2022-2025 | |
| Pfizer INC. | $63.89 | 2024-2025 | |
| Beone Medicines USA, INC. | $52.56 | 2025 | Brukinsa, Tevimbra |
| Glaxosmithkline, LLC. | $49.45 | 2024-2025 | Ojjaara |
| Taiho Oncology, INC. | $45.47 | 2022-2024 | |
| Myovant Sciences INC. | $39.68 | 2022 | |
| Adaptive Biotechnologies Corporation | $36.85 | 2023-2025 | Clonoseq |
| G1 Therapeutics, INC. | $36.27 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.82 | 2025 | |
| Cti Biopharma Corp. | $32.89 | 2022-2023 | Vonjo |
| Ipsen Biopharmaceuticals, INC | $30.64 | 2022-2024 | Onivyde |
| Springworks Therapeutics, INC. | $30.64 | 2025 | Ogsiveo |
| Dendreon Pharmaceuticals LLC | $30.02 | 2024 | Provenge |
| Geron Corporation | $29.36 | 2025 | Rytelo |
| Menarini Silicon Biosystems, INC. | $24.72 | 2025 | |
| Nuvation Bio INC. | $21.39 | 2025 | Ibtrozi |
| Tempus Ai, INC | $20.63 | 2024 | |
| Kite Pharma, INC. | $19.06 | 2025 | Yescarta |
| Amneal Pharmaceuticals LLC | $17.93 | 2025 | Alymsys |
| Agios Pharmaceuticals, INC. | $17.01 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $16.93 | 2021 | |
| Legend Biotech USA INC. | $16.66 | 2025 | Carvykti |
| Rigel Pharmaceuticals, INC. | $16.63 | 2024 | Tavalisse, Rezlidhia |
| Coopersurgical, INC. | $16.62 | 2025 | Paragard T 380a |
| Gilead Sciences, INC. | $16.51 | 2023 | |
| Apellis Pharmaceuticals, INC. | $15.08 | 2022 | |
| Morphosys, US INC. | $13.77 | 2023 | Monjuvi |
| Pharmacosmos Therapeutics INC. | $12.82 | 2023 | Monoferric |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.